Medications to Manage Constipation on Zepbound (tirzepatide): First-Line and Beyond

How often does Zepbound cause constipation?

In the pooled weight-management trials, constipation, including hard stools, was reported in 17% of people on 5 mg, 14% on 10 mg and 11% on 15 mg, against 5% on placebo [2]. Those numbers come from two randomized, double-blind, placebo-controlled trials that treated adults with obesity or overweight, with or without type 2 diabetes, for up to 72 weeks [2]. The rate was highest at 5 mg and lowest at 15 mg.

Gastrointestinal reactions as a group were far more common than constipation alone: 56% on every Zepbound dose versus 30% on placebo, and 1.9%, 3.3% and 4.3% of patients stopped treatment for a gastrointestinal reaction at 5, 10 and 15 mg versus 0.5% on placebo [2]. The label states that most nausea, vomiting and diarrhea occurred during dose escalation and decreased over time; it makes no equivalent statement about constipation [2].

What the PEG label says, and where the guideline goes further

Polyethylene glycol 3350 is an osmotic laxative sold over the counter [3]. The MiraLAX Drug Facts label directs adults 17 and older to use 17 g once a day, stirred into 4 to 8 ounces of beverage, and limits self-use to 7 days [3]. It describes the product as relieving occasional constipation and generally producing a bowel movement in 1 to 3 days [3].

The same label says to stop using it if rectal bleeding occurs, if nausea, bloating, cramping or abdominal pain gets worse, if diarrhea occurs, or if a laxative is needed for longer than 1 week, and calls these possible signs of a serious condition [3]. Its before-use section names nausea, vomiting or abdominal pain, a sudden change in bowel habits lasting over 2 weeks, and irritable bowel syndrome [3]. It also says people with kidney disease should not use it except under medical supervision [3].

The AGA/ACG guideline is a different kind of document: recommendations for adults with chronic idiopathic constipation, built on systematic reviews of specific agents [1]. It strongly recommends PEG, and uses the same strong wording for sodium picosulfate, linaclotide, plecanatide and prucalopride [1]. Conditional recommendations cover fiber, lactulose, senna, magnesium oxide and lubiprostone [1]. That is 10 recommendations in total, written for a chronic idiopathic condition and not for constipation caused by another drug [1].

Bisacodyl was one of the stimulant laxatives the panel reviewed, but it is not among the 10 recommendations; sodium picosulfate and senna are [1]. Docusate is not among the agents the panel reviewed [1].

Prescription options: what is actually labeled

Linaclotide (Linzess) is a guanylate cyclase-C agonist whose labeled indications are IBS-C in adults and children 7 and older, chronic idiopathic constipation in adults, and functional constipation in children 2 and older [4]. The adult chronic idiopathic constipation dose is 145 mcg once daily, or 72 mcg once daily depending on presentation or tolerability; the adult IBS-C dose is 290 mcg once daily [4]. It is taken on an empty stomach at least 30 minutes before a meal, and it is contraindicated in known or suspected mechanical gastrointestinal obstruction [4]. The label warns that patients may experience severe diarrhea, in which case dosing is suspended and the patient rehydrated [4]. Constipation caused by tirzepatide is not among the labeled indications [4].

Lubiprostone, plecanatide and prucalopride also appear in the guideline, with strong recommendations for plecanatide and prucalopride and a conditional recommendation for lubiprostone [1].

Dose decisions follow the Zepbound label's rules

Zepbound starts at 2.5 mg once weekly for 4 weeks — an initiation dose that is not approved as a maintenance dose — then moves to 5 mg, with further 2.5 mg increases after at least 4 weeks on the current dose [2]. Maintenance is 5, 10 or 15 mg weekly for weight reduction and 10 or 15 mg for obstructive sleep apnea [2]. The label says to consider treatment response and tolerability when selecting the maintenance dose, and to consider a lower maintenance dose if a maintenance dose is not tolerated [2]. Constipation was reported at 17%, 14% and 11% across 5, 10 and 15 mg, so the lowest dose had the highest rate [2].

What the labels say to watch for

The Zepbound label warns about severe gastrointestinal adverse reactions, which were reported in 1.7%, 2.5% and 3.1% of patients at 5, 10 and 15 mg versus 1% on placebo, and states that the drug is not recommended in people with severe gastroparesis [2]. Acute kidney injury from volume depletion is a labeled warning, and the label says to monitor renal function in patients reporting reactions that could lead to volume depletion, especially during dose initiation and escalation [2]. Acute pancreatitis is another labeled warning: the label describes persistent or severe abdominal pain, sometimes radiating to the back, and says to discontinue Zepbound if pancreatitis is suspected [2].

For the laxative itself, the MiraLAX label lists rectal bleeding, diarrhea, and worsening nausea, bloating, cramping or abdominal pain as possible signs of a serious condition [3].

Do oral medicines behave differently on Zepbound?

Tirzepatide delays gastric emptying, and the label says this has the potential to affect absorption of oral medicines [2]. It advises monitoring for oral drugs dependent on threshold concentrations or with a narrow therapeutic index, naming warfarin as an example [2].